TroyGould represents LIXTE Biotechnology Holdings, Inc. in its $3.5 Million Public Offering

TroyGould represented LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT and LIXTW) in a recent $3.5 million registered direct offering of 583,334 shares of its common stock (or common stock equivalents in lieu thereof) and concurrent private placement of common warrants to purchase up to 583,334 shares of common stock at a purchase price of $6.00 per common share, priced “at-the-market” under Nasdaq rules. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies.  A.G.P./Alliance Global Partners acted as sole placement agent for the offering. The TroyGould team was led by David Ficksman with support from William Hubbard. For more information, see this press release.

 

About TroyGould

Celebrating 50 years of success as one of Southern California’s leading business law firms, TroyGould is recognized in the U.S. and abroad for its success in helping both U.S. and non-U.S entities and individuals achieve their business goals. The firm’s transactional and litigation clients range from emerging companies to middle-market and Fortune 500 companies across a diverse set of industries including life sciences, technology, entertainment/media, manufacturing, food and beverage, real estate, consumer products and health care. For more information, visit TroyGould.com.